These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33421580)

  • 1. Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.
    Eyal N; Lipsitch M
    Clin Microbiol Infect; 2021 Mar; 27(3):372-377. PubMed ID: 33421580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.
    Steel R; Buchak L; Eyal N
    J Med Ethics; 2020 Dec; 46(12):808-812. PubMed ID: 32661074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies.
    Steuwer B; Jamrozik E; Eyal N
    Int J Infect Dis; 2021 Apr; 105():307-311. PubMed ID: 33592338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
    Rohrig A; Eyal N
    J Infect Dis; 2022 Mar; 225(6):934-937. PubMed ID: 34624095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Broockman D; Kalla J; Guerrero A; Budolfson M; Eyal N; Jewell NP; Magalhaes M; Sekhon JS
    Vaccine; 2021 Jan; 39(2):309-316. PubMed ID: 33334616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal COVID-19 vaccines: From bench to bed.
    Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
    EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning from the past: development of safe and effective COVID-19 vaccines.
    Su S; Du L; Jiang S
    Nat Rev Microbiol; 2021 Mar; 19(3):211-219. PubMed ID: 33067570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants.
    Su S; Shao Y; Jiang S
    Emerg Microbes Infect; 2021 Dec; 10(1):439-441. PubMed ID: 33635184
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why Oxford's positive COVID vaccine results are puzzling scientists.
    Callaway E
    Nature; 2020 Dec; 588(7836):16-18. PubMed ID: 33230278
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
    Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.